192 related articles for article (PubMed ID: 27871834)
21. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Shavi GV; Sreenivasa Reddy M; Raghavendra R; Nayak UY; Kumar AR; Deshpande PB; Udupa N; Behl G; Dave V; Kushwaha K
J Liposome Res; 2016; 26(1):28-46. PubMed ID: 25853340
[TBL] [Abstract][Full Text] [Related]
22. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
23. Enhanced depigmenting effects of N-glycosylation inhibitors delivered by pH-sensitive liposomes into HM3KO melanoma cells.
Park JY; Choi H; Hwang JS; Kim J; Chang IS
J Cosmet Sci; 2008; 59(2):139-50. PubMed ID: 18408871
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
26. Mixtures of hyaluronic acid and liposomes for drug delivery: Phase behavior, microstructure and mobility of liposomes.
El Kechai N; Geiger S; Fallacara A; Cañero Infante I; Nicolas V; Ferrary E; Huang N; Bochot A; Agnely F
Int J Pharm; 2017 May; 523(1):246-259. PubMed ID: 28323101
[TBL] [Abstract][Full Text] [Related]
27. Disaccharide-modified liposomes and their in vitro intracellular uptake.
Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
[TBL] [Abstract][Full Text] [Related]
28. Effects of liposomal phospholipids and lipid transport-related protein on the intracellular fate of encapsulated doxorubicin.
Un K; Sakai-Kato K; Kawanishi T; Okuda H; Goda Y
Mol Pharm; 2014 Feb; 11(2):560-7. PubMed ID: 24383572
[TBL] [Abstract][Full Text] [Related]
29. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
30. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
31. Curcumin loaded pH-sensitive hybrid lipid/block copolymer nanosized drug delivery systems.
Jelezova I; Drakalska E; Momekova D; Shalimova N; Momekov G; Konstantinov S; Rangelov S; Pispas S
Eur J Pharm Sci; 2015 Oct; 78():67-78. PubMed ID: 26159739
[TBL] [Abstract][Full Text] [Related]
32. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
33. Topical drug delivery to retinal pigment epithelium with microfluidizer produced small liposomes.
Lajunen T; Hisazumi K; Kanazawa T; Okada H; Seta Y; Yliperttula M; Urtti A; Takashima Y
Eur J Pharm Sci; 2014 Oct; 62():23-32. PubMed ID: 24810393
[TBL] [Abstract][Full Text] [Related]
34. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration.
Kuai R; Yuan W; Li W; Qin Y; Tang J; Yuan M; Fu L; Ran R; Zhang Z; He Q
Mol Pharm; 2011 Dec; 8(6):2151-61. PubMed ID: 21981683
[TBL] [Abstract][Full Text] [Related]
35. Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs.
Arouri A; Mouritsen OG
Eur J Pharm Sci; 2012 Mar; 45(4):408-20. PubMed ID: 21946258
[TBL] [Abstract][Full Text] [Related]
36. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
37. In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer.
Kim CE; Lim SK; Kim JS
J Control Release; 2012 Jan; 157(2):190-5. PubMed ID: 21963773
[TBL] [Abstract][Full Text] [Related]
38. Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes.
Celia C; Calvagno MG; Paolino D; Bulotta S; Ventura CA; Russo D; Fresta M
J Nanosci Nanotechnol; 2008 Apr; 8(4):2102-13. PubMed ID: 18572621
[TBL] [Abstract][Full Text] [Related]
39. Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.
Xu M; Qian J; Liu X; Liu T; Wang H
Mater Sci Eng C Mater Biol Appl; 2015 May; 50():341-7. PubMed ID: 25746279
[TBL] [Abstract][Full Text] [Related]
40. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery.
Lee RJ; Wang S; Turk MJ; Low PS
Biosci Rep; 1998 Apr; 18(2):69-78. PubMed ID: 9743475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
